Answers are grounded in this paper and cite their sources.
Antimicrobial resistance is a major global health challenge, leading to adverse clinical outcomes, increased healthcare costs, and diminished efficacy of antimicrobials. Clinical pharmacists, with advanced pharmacotherapy expertise and direct involvement in patient care, are well positioned to optimize treatment while helping to combat resistance. This narrative review compiles evidence from bibliographic databases covering literature published between January 2021 and October 2025. It assesses the clinical, economic, and operational impact of clinical pharmacists working within infectious diseases services and antimicrobial stewardship programs. The evidence indicates that these professionals enhance antimicrobial prescribing through stewardship leadership, pharmacokinetic/pharmacodynamic-guided dose optimization, rapid diagnostic stewardship, intravenous-to-oral switch programs, and the resolution of drug-related problems. Collaborative drug therapy management within antimicrobial stewardship programs can reduce antimicrobial expenditure by approximately 34.0%. Nevertheless, the available evidence remains heterogeneous and largely observational, with most data originating from high-income countries, which limits generalizability. Despite growing evidence of benefit, clinical pharmacy services remain underutilized in some low- and middle-income countries due to structural constraints, limited training opportunities, and workforce shortages. To optimize antimicrobial use and patient outcomes, health systems should better integrate infectious diseases clinical pharmacists into multidisciplinary teams, strengthen diagnostic capacity, and embed antimicrobial stewardship principles within pharmacy education. Clinical pharmacists have become integral clinical partners in infection management and prevention, with the potential to improve individual patient outcomes and contribute to greater antimicrobial resistance mitigation. Improving their role represents a strategic priority for preserving antimicrobial efficacy and enhancing patient safety.
No takes yet. Share an insight, caveat, or question.
Elmezughi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: